Yezan Munther Haddadin - Oct 6, 2022 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role: Director
Signature: /s/ Lawrence Kenyon, Attorney-in-Fact
Stock symbol: OTLK
Transactions as of: Oct 6, 2022
Transactions value $: $42,940
Form type: 4
Date filed: 10/11/2022, 05:05 PM
Previous filing: Oct 7, 2022
Next filing: Mar 31, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OTLK	Common Stock	Purchase	$38.4K	+29.7K	+99.14%	$1.29	59.7K	Oct 6, 2022	Direct	F1
transaction	OTLK	Common Stock	Purchase	$4.57K	+3.6K	+6.03%	$1.27	63.3K	Oct 7, 2022	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.279 - $1.2915, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.279 - $1.2915, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.